ASH 2023 | Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses findings from the CLL12 trial (NCT02863718), focusing on genetic markers that have predictive and prognostic value in patients with early-stage chronic lymphocytic leukemia (CLL) who are treated with ibrutinib. The study found improved event-free survival (EFS) in patients treated with ibrutinib compared to placebo, particularly benefiting those with unmutated IGHV. However, ibrutinib had no impact on overall survival (OS), indicating that the current standard-of-care (SoC) for early CLL should remain as observation without immediate intervention. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Honoraria: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Travel support: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Research Funding: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca.
